AbbVie: earnings against revised guidance
AbbVie’s October 30 outlook raises adjusted diluted EPS to $13.95–$13.99, including year-to-date acquired-IPR&D and milestone expense. Future charges can still affect delivery.
AbbVie / ABBVPublic biotechEarningsDate to watch
What matters
Watch product sales, guidance and cash needs alongside the headline result. Company filings and the earnings release provide the primary evidence.
Primary evidence
Reporting date unconfirmed — research candidate
AbbVie Q3 2026 resultsPublished 2026-10-30
Potential outcome market
Will AbbVie 2026 adjusted diluted EPS exceed $13.97?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.